title: Appropriateness of cardiovascular care in elderly adult cancer survivors.
abstract: Research suggests that the quality of non-cancer-related care among cancer survivors (CS) is suboptimal. Secondary disease prevention is an important component of survivorship care that has not been previously evaluated. Our aims were (1) to assess the utilization of and adherence to medications and treatments for the secondary prevention of myocardial infarction (MI) in CS versus non-cancer patients (NCP) and (2) to compare temporal trends in cardiovascular care between these two patient cohorts. Linking data from Medicare, pharmacy assistance programs, and cancer registries, we calculated the percentage of individuals receiving preventive medications (statins, β-blockers, angiotensin-converting enzyme inhibitors) and revascularization interventions (angioplasty, stent, bypass surgery) within 90 days after acute MI in CS and propensity score-matched NCP. We assessed trends over time and determined predictors of appropriate preventive care using modified Poisson regression. We identified 1,119 CS and 7,886 NCP. Compared to NCP, more survivors received statins (38 vs. 31 %) and β-blockers (67 vs. 59 %), but fewer underwent bypass surgery (1.5 vs. 2.8 %) after MI. From 1997 to 2004, both survivors and NCP were increasingly prescribed medications to prevent future coronary events. Over the same time period, receipt of bypass surgery was significantly lower among survivors. Co-morbidities, such as depression and lung disease, and demographic factors, such as advanced age and female, were associated with underuse of preventive care among survivors when compared to NCP. Use of preventive medications and procedures has generally improved, but uptake of bypass surgery among CS still lags behind NCP.
authors.affiliation: Division of Medical Oncology, British Columbia Cancer Agency, 600 W. 10th Ave., 4th Floor, Vancouver, BC, V5Z 4E6, Canada. wcheung@bccancer.bc.ca
authors.forename: Winson Y
authors.initials: WY
authors.lastname: Cheung
authors.forename: Raisa
authors.initials: R
authors.lastname: Levin
authors.forename: Soko
authors.initials: S
authors.lastname: Setoguchi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D006348:Cardiac Surgical Procedures / Q000706:statistics & numerical data; D002317:Cardiovascular Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000517:prevention & control / Q000601:surgery / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000503:physiopathology*; D011314:Preventive Health Services; D012189:Retrospective Studies; D017741:Survivors; D016903:Drug Monitoring
chemical_list: D002317:Cardiovascular Agents
references.citation: Am Heart J. 2007 Sep;154(3):461-9
references.pmid: 17719291
references.citation: Med Care. 2002 Aug;40(8 Suppl):IV-19-25
references.pmid: 12187164
references.citation: J Clin Oncol. 2008 Mar 1;26(7):1073-9
references.pmid: 18309941
references.citation: Healthc Policy. 2009 Nov;5(2):68-86
references.pmid: 21037827
references.citation: J Chronic Dis. 1987;40(5):373-83
references.pmid: 3558716
references.citation: Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1893-907
references.pmid: 20647400
references.citation: J Natl Cancer Inst. 2002 May 1;94(9):652-61
references.pmid: 11983753
references.citation: Drug Saf. 1992 Jan-Feb;7(1):14-31
references.pmid: 1536695
references.citation: Am Heart J. 2004 Jul;148(1):99-104
references.pmid: 15215798
references.citation: J Clin Oncol. 2011 Jun 20;29(18):2534-42
references.pmid: 21606426
references.citation: Cancer. 2004 Oct 15;101(8):1712-9
references.pmid: 15386307
references.citation: Lancet Oncol. 2011 Dec;12(13):1249-57
references.pmid: 21741307
references.citation: J Clin Epidemiol. 1997 Jan;50(1):105-16
references.pmid: 9048695
references.citation: Med Care. 2002 Aug;40(8 Suppl):IV-3-18
references.pmid: 12187163
references.citation: J Clin Oncol. 2010 Sep 20;28(27):4120-8
references.pmid: 20585090
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Curr Hypertens Rep. 2010 Aug;12(4):226-32
references.pmid: 20514556
references.citation: JAMA. 2007 Jan 10;297(2):177-86
references.pmid: 17213401
references.citation: Am Heart J. 2004 Jun;147(6):1010-6
references.pmid: 15199349
references.citation: J Gen Intern Med. 2008 Mar;23(3):254-9
references.pmid: 18197456
references.citation: Health Care Financ Rev. 2008 Summer;29(4):69-80
references.pmid: 18773615
references.citation: Qual Saf Health Care. 2006 Oct;15(5):339-43
references.pmid: 17074870
references.citation: J Natl Cancer Inst Monogr. 2010;2010(40):25-30
references.pmid: 20386051
references.citation: Am J Epidemiol. 2004 Apr 1;159(7):702-6
references.pmid: 15033648
references.citation: J Clin Lipidol. 2008 Feb;2(1):51-7
references.pmid: 21291715
references.citation: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references.pmid: 20610543
references.citation: Lancet Oncol. 2008 Mar;9(3):232-8
references.pmid: 18282804
references.citation: Health Technol Assess. 2004 Sep;8(35):iii-iv, 1-242
references.pmid: 15361315
references.citation: Future Cardiol. 2011 May;7(3):311-20
references.pmid: 21627473
references.citation: Circulation. 2011 May 10;123(18):2022-60
references.pmid: 21444889
references.citation: N Engl J Med. 2005 Aug 4;353(5):487-97
references.pmid: 16079372